Authors from the University of Vermont comment on the limitations of, and assumptions inherent in, the tools used by clinicians to detect and monitor acute kidney injury. After discussing the pitfalls associated with use of serum creatinine level and glomerular filtration rate, Solomon and Segal recommend means by which trial design can be improved while awaiting development and validation of more-accurate biomarkers of renal function.
- Richard Solomon
- Alan Segal
